College of Pharmacy, Ewha Womans University, Seoul 03760, Korea.
Department of Statistics, Ewha Womans University, Seoul 03760, Korea.
Int J Environ Res Public Health. 2021 Mar 18;18(6):3139. doi: 10.3390/ijerph18063139.
This study sought to adapt the existing value framework (VF) to produce a reliable and valid Korean oncology VF. Two VFs developed by The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) were selected for examination in the present study. Forward and backward translations were conducted for six high-priced drugs indicated for non-small-cell lung cancer and multiple myeloma. Inter-rater reliability was measured based on the intraclass correlation coefficient (ICC) and variation was described using the coefficient of variation. The relative weights of factors critically considered by Korean oncologists were derived following the analytic hierarchy process (AHP), and focus group interviews (FGIs) were used to obtain qualitative data regarding the applications of these two VFs in the Korean setting. The ICCs of the Korean VFs were 0.895 (0.654-0.983) for ASCO and 0.726 (0-0.982) for ESMO translations, suggesting excellent reliability for ASCO and good reliability for ESMO. AHP demonstrated that clinical benefit has the highest priority, which is consistent with the ASCO VF. The FGIs suggested that the result for AHP is acceptable and that both ESMO and ASCO VFs should be used complementarily. Although further evaluation with a larger sample size is needed, the Korean versions of ESMO/ASCO VFs are valid and reliable tools and are acceptable to Korean stakeholders, yet they should be applied with caution.
本研究旨在改编现有的价值框架（VF），以生成可靠且有效的韩国肿瘤学 VF。本研究选择了美国临床肿瘤学会（ASCO）和欧洲肿瘤内科学会（ESMO）开发的两个 VF 进行检查。对用于非小细胞肺癌和多发性骨髓瘤的六种高价药物进行了正向和逆向翻译。根据组内相关系数（ICC）测量了评分者间信度，并使用变异系数描述了变异。韩国肿瘤学家认为至关重要的因素的相对权重是根据层次分析法（AHP）得出的，并通过焦点小组访谈（FGI）获得了有关这两个 VF 在韩国应用的定性数据。ASCO 翻译的韩国 VF 的 ICC 为 0.895（0.654-0.983），ESMO 翻译的 ICC 为 0.726（0-0.982），表明 ASCO 的信度非常好，ESMO 的信度良好。AHP 表明临床获益具有最高优先级，这与 ASCO VF 一致。FGI 表明 AHP 的结果是可以接受的，ESMO 和 ASCO VF 都应该互补使用。尽管需要进一步用更大的样本量进行评估，但 ESMO/ASCO VF 的韩语版本是有效且可靠的工具，并且被韩国利益相关者所接受，但应谨慎应用。
